Overview of IASLC-WCLC 2024

The World Conference on Lung Cancer (WCLC) 2024, scheduled for Sept. 7-10 in San Diego, Calif., USA, will be a gathering in thoracic oncology under the leadership of Sandip Patel (University of California, USA), Linda Martin (University of Virginia, USA), Narjust Florez (Dana-Farber Cancer Institute, USA), and Fabio Ynoe de Moraes (Queen’s University, Canada).

This conference will provide thorough insights into the most recent developments in lung cancer research and treatment.

IASLC-WCLC Day 1: September 7, 2024

The conference begins with workshops and sessions centered on essential aspects of lung cancer treatment. The main sessions will consist of the following:

• Exploring Advanced Diagnostic Techniques for Early Detection of Lung Cancer:

  • This workshop will focus on transitioning valuable early diagnostic tools from research to clinical practice.

  • Speakers will be Stephen Deppen (Vanderbilt University), Karen Anderson (Arizona State University), Michael Nolan Kammer (Vanderbilt University), Alex Kaizer (University of Colorado Anschutz Medical Campus), Anna Baron (University of Colorado), and Yency Forero (Vanderbilt University).

• Collaborative IASLC-CSCO-CAALC Session: 
  • A global expert discussion focussing on the past and future outlook of lung cancer prevention and evidence-based medicine.
  • The session will be chaired by Chunxue Bai (Zhongshan Hospital Fudan University, Shanghai, China), Karen Kelly ( University of California), Yi-Long Wu (Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangzhou, China), and Caicun Zhou (Shanghai Pulmonary Hospital, Shanghai, China).
• Persuasive communication:
  • Improving communication skills in oncology through persuasive communication.
  • Speakers will be Annabelle Gurwitch (Actress and Author) and Mónica Adriana Castro (Buenos Aires, Argentina Instituto de Oncología Ángel H. Roffo).

Industry-sponsored Symposia:

• Johnson & Johnson will be discussing a new and creative initial treatment choice for EGFR+ locally advanced or metastatic non-small cell lung cancer (NSCLC).
• Amgen will be introducing revolutionary advancements with Bispecific T-cell Engager (BiTE®) therapy for extensive-stage small cell lung cancer (ES-SCLC).

IASLC-WCLC 2024 | Satellite CME Symposia:

• PeerView session (2:30 p.m. – 3:30 p.m.): Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC
  • This session will offer a useful structure for optimal biomarker testing, treatment selection, sequencing, and adverse events management.
  • Speakers will be Natasha B. Leighl (Princess Margaret Cancer Centre, Toronto, ON, Canada), Luis Paz-Ares (Oncology, Hospital 12 de Octubre, Madrid, Spain), and Joshua K. Sabari (Perlmutter Cancer Center, NYU Langone Health, New York, N.Y.).
• Physicians’ Education Resource (2:30 p.m. – 3:30 p.m.): Do We Have Sea Change in Small Cell Lung Cancer?
  • This symposium will evaluate new clinical trial data and emerging novel approaches to treatment decisions.
  • Speakers will be Anne Chiang (Yale University School of Medicine, New Haven, Conn.), Jonathan W. Riess (UC Davis Comprehensive Cancer Center, Sacramento, Calif.), and Misty Dawn Shields (Indiana University School of Medicine, Indianapolis, Ind.).

In the afternoon, workshops like the Early Career Investigator Workshop and the IASLC CT Screening Symposium will offer in-depth insights and networking opportunities. The day will conclude with the IASLC Award Ceremony and the Opening Plenary Session, featuring distinguished service award presentations.

IASLC-WCLC Day 2: September 8, 2024

The day 2 will present the latest findings and clinical practices.
Some of the highlights include:

• Meet the Expert Sessions: It will include some critical topics like the role of surgery in pleural mesothelioma, lung cancer screening, digital health for supportive care, and advances in cell therapy.
  • Speakers will be Marc DePerrot (University Health Network, ON, Canada), Kenneth O’Byrne (Princess Alexandra Hospital, Australia), Gerard A. Silvestri (Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, S.C.), Kevin Ten Haaf (Erasmus University Medical Center Rotterdam, Netherlands), Jennifer Temel (Massachusetts General Hospital), Cristiane Decat Bergerot (MEDSIR, Brasilia, Brazil), Martin Forster (University College London) and Amy Moore (LUNGevity Foundation, Kan.).
• Presidential Symposium 1: A major plenary session to be livestreamed, highlighting significant research findings and developments.
• Education Sessions: Discussions will cover challenges in immunotherapy, improving access to lung cancer screening, and novel therapeutic options for small-cell lung cancer.

  • The session will be chaired by Clarissa Baldotto (Clinica Research, Instituto D’Or for Research and Education, Rio de Janeiro, Brazil) and Misako Nagasaka (Barbara Ann Karmanos Cancer Institute, Mich.).

    Speakers will be Arielle Elkrief (University of Montreal, QC, Canada), David R. Gandara (UC Davis Medical Center, Sacramento, Calif.), and Siow Ming Lee (University College London Hospitals NHS Foundation Trust, CRUK, United Kingdom).

IASLC-WCLC 2024 | Industry-sponsored Symposia:

• Flatiron Health: To offer insights into global real-world evidence for biomarker-defined lung cancer cohorts.
• BMS Foundation: To focus on continuity of care in lung cancer management.
• Pfizer Oncology: To review the efficacy and safety data of LORBRENA® (lorlatinib) from the CROWN trial.
• Abbvie: To address unmet needs in NSCLC with emerging ADCs targeting c-Met.

IASLC-WCLC 2024| Satellite CME Symposia:

• Physicians’ Education Resource:
  • Future perspectives on HER2- and Trop2-directed ADCs in lung cancer.
  • Speakers will be Jacob Sands (Dana Farber Cancer Institute, Mass.), Aaron Lisberg (UCLA Santa Monica Cancer Center, Santa Monica, Calif.), and Myung-Ju Ahn (Sungkyunkwan University School of Medicine, Seoul, Korea).

IASLC-WCLC Day 3: September 9, 2024

The day 3 will feature a range of impactful sessions:

• Highlights of the Day: Recapping key presentations and findings from Sunday’s sessions.
• Expert Sessions: The session will discuss challenges in lung cancer imaging, the importance of patient advocates in research, and learn about KRAS-driven lung cancers.

  • Speakers will be Ioannis Vlahos (The University of Texas MD Anderson Cancer Center, Texas), Constance de Margerie-Mellon (Université de Paris – Hôpital Saint-Louis APHP, France), Merel Hennink (Longkanker Nederland, Netherlands), Anthonie van der Wekken (University Medical Centre Groningen, Netherlands), Miriam Molina-Arcas (Francis Crick Institute) and Piro Lito (Memorial Sloan Kettering Cancer Center, N.Y.).

• Presidential Symposium 2: Live broadcast plenary session showcasing major developments in lung cancer research.

  • The session will be chaired by Caicun Zhou and Heather Wakelee (Medicine-Oncology, Stanford University, Stanford, Calif).

• Educational sessions: This will cover updates on mesothelioma, expanding eligibility for lung cancer screening, and new immunotherapy choices.

  • Mesothelioma session will be chaired by Sonja Klebe (SA Pathology, Australia).

    Speakers will be Flavia Gabrielli (Instituto do Câncer do Estado de São Paulo, Brazil), Josh Sonett (Columbia University/New York-Presbyterian Hospital, NY), and John Le Quesne (University of Glasgow, Glasgow, United Kingdom).

  • The expanding screening eligibility session will be chaired by Chi-Fu Jeffrey Yang (Massachusetts General Hospital, Mass.) and Annette Maree McWilliams (Fiona Stanley Hospital, Perth, Australia).

    Speakers will be Elaine Shum (NYU Langone Health, N.Y.), Anna Kerpel-Fronius (National Korányi Institute for Pulmonology, Hungary), Randi William (Georgetown University Medical Center, Washington, D.C.) and Erica Warner (Massachusetts General Hospital, Mass.).

  • The novel immunotherapy session will be chaired by Luis  Raez (Memorial Cancer Institute/Florida Atlantic University, Boca Raton, Fla.) and Delvys Rodriguez-Abreu  (Hospital Universitario Insular de Gran Canaria, Spain).

    Speakers will be Charu Aggarwal (University of Pennsylvania, Philadelphia, Penn.), Ben Creelan (H. Lee Moffitt Cancer Center and Research Institute, Fla.), Wen-Zhao Zhong (GLCI, China) and Alfredo Addeo (University Hospital Geneva, Switzerland).

IASLC-WCLC 2024 | Industry-sponsored Symposia:

• Roche Diagnostics: To explore Useful Biomarkers in Initial NSCLC Stages.
• Thermo Fisher Scientific: To discuss next-day NGS and its impact on precision oncology.

IASLC-WCLC 2024 | Satellite CME Symposia:

• PeerView (12:30 p.m. – 1:30 p.m.): Enhancing Treatment in Stage I-III NSCLC with Targeted Therapy and Immunotherapy in Multimodal Approaches.
  • Speakers will be Roy S. Herbst (Yale Cancer Center, Smilow Cancer Hospital, New Haven, Conn.), Tetsuya Mitsudomi (Kindai University Faculty of Medicine, Japan), and Tina Cascone (The University of Texas MD Anderson Cancer Center, Houston, Texas).
• Physicians’ Education Resource (6:15 p.m.- 7:15 p.m.): Enhancing precision medicine through advancements in molecular testing for MET, RET, and KRAS-altered NSCLC.
  • Speakers will be Charu Aggarwal, Karen Reckamp (Cedars-Sinai Medical Center, Los Angeles, Calif.) and Christine M. Bestvina (University of Chicago Medicine, Chicago, Ill.), and Hatim Husain (University of California San Diego, La Jolla, Calif.).

IASLC-WCLC Day 4: September 10, 2024

The final day will summarize the conference and provide additional insights:

• • Highlights of the Day: Recapping key presentations and findings from Monday’s sessions.

The day will feature various sessions like:

• New Paradigms in Lung Cancer Screening

  • This session will explore emerging strategies in lung cancer screening, offering fresh insights into early detection methods. It is not eligible for CME credit.

  • The session will be chaired by Loretta Erhunmwunsee (City of Hope, Duarte, Calif.) and Long Jiang (Shanghai Chest Hospital, China).

• Innovative Therapeutic Approaches and Molecular Insights in Lung Cancer

  • This session will highlight cutting-edge therapeutic approaches and molecular discoveries in lung cancer. It is also not eligible for CME credit.

  • The session will be chaired by Sandra Ortiz-Cuaran (Cancer Research Center of Lyon, France) and Hongbin Ji (Shanghai Institute of Biochemistry and Cell Biology, CAS Center for Excellence in Molecular Cell Science Chinese Academy of Sciences, Shanghai, China).

IASLC-WCLC 2024 Business Meeting and Press Conference

• The IASLC Business Meeting will be livestreamed. Presenters will be Paul E. Van Schil (University Hospital Antwerp, Belgium), Karen Kelly, Jennifer C. King (IASLC, Denver, Colo.), Joachim G.J.V. Aerts (Erasmus University Medical Center, Rotterdam, Netherlands), and Alex Adjei (Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio).
• The IASLC-WCLC will conclude with a press conference, where the latest updates and future directions in lung cancer research and treatment will be discussed.

IASLC-WCLC 2024 Exhibitors

According to even to organizers, the following will also be exhibiting at the conference:

• Akesobio
• ALCMI (Addario Lung Cancer Medical Institute)
• AACR
• Amgen
• Amoy Diagnostics
• AstraZeneca
• Bayer
• Biocartis
• Biofidelity
• BioNTech
• Boehringer Ingelheim
• Bristol Myers Squibb
• Burning Rock Dx
• Caris Life Sciences
• Catalyst
• Daiichi Sankyo
• DAVA Oncology
• EMD Serono
• Exact Sciences
• Fosun Pharma USA
• Foundation Medicine
• Genentech
• Genmab
• Gilead
• GSK
• Guardant Health
• Johnson & Johnson
• Jazz Pharmaceuticals
• Lilly
• Median Technologies
• Merck